A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors



Status:Archived
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:June 2008
End Date:May 2011

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

The purpose of this study is to determine the maximum tolerated dose (MTD), safety,
tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of
E6201 in subjects with advanced solid tumors.



We found this trial at
9
sites
Clinical Trial Facility
Richmond, Virginia
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Clinical Trial Facility
Albany, New York
?
mi
from
Albany, NY
Click here to add this to my saved trials
Clinical Trial Facility
Austin, Texas
?
mi
from
Austin, TX
Click here to add this to my saved trials
Clinical Trial Facility
Charleston, South Carolina
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Clinical Trial Facility
Henderson, Nevada
?
mi
from
Henderson, NV
Click here to add this to my saved trials
Clinical Trial Facility
Lebanon, New Hampshire
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
Clinical Trial Facility
Mountlake Terrace, Washington
?
mi
from
Mountlake Terrace, WA
Click here to add this to my saved trials
Clinical Trial Facility
Peoria, Arizona
?
mi
from
Peoria, AZ
Click here to add this to my saved trials
Clinical Trial Facility
Santa Clara, California 95051
?
mi
from
Santa Clara, CA
Click here to add this to my saved trials